BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced the closing of a $150 million Series C financing. The financing was co-led by Frazier Life Sciences and Lightspeed Venture Partners, and included additional new support from Willet Advisors and leading healthcare institutional investors, along with existing investors Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity Management & Research Company, Boxer Capital, EcoR1 Capital, LLC, Surveyor Capital (a Citadel company), Invus, Wellington Management, Nextech Invest Ltd.

波士顿--（商业新闻短讯）--Scorpion Therapeutics，Inc.（“Scorpion”）是一家开创性的临床阶段肿瘤学公司，致力于通过重新定义精确肿瘤学的前沿来改变癌症患者的生活，今天宣布关闭1.5亿美元的C系列融资。该融资由Frazier Life Sciences和Lightspeed Venture Partners共同牵头，包括Willet Advisors和领先的医疗保健机构投资者以及现有投资者Omega Funds、Vida Ventures、Atlas Venture、Abingworth、Fidelity Management&Research Company、Boxer Capital、EcoR1 Capital，LLC、Surveyor Capital（Citadel Company）、Invus、惠灵顿管理公司、Nextech Invest Ltd.提供的额外新支持。

(on behalf of one or more funds managed by it), OrbiMed, Logos Capital, Woodline Partners LP, and Casdin Capital, LLC. In connection with the financing, Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners, will transition to an investor board member and Albert Cha, M.D., Ph.D., Managing Partner at Frazier Life Sciences, will join Scorpion's board as an observer..

（代表其管理的一个或多个基金）、OrbiMed、Logos Capital、Woodline Partners LP和Casdin Capital，LLC。在融资方面，Lightspeed Venture Partners合伙人Shelley Chu医学博士将过渡为投资者董事会成员，Frazier Life Sciences管理合伙人Albert Cha医学博士将以观察员身份加入Scorpion董事会。。

“The robust demand for this capital raise is a testament to Scorpion's continued clinical execution, the strength of our emerging clinical data, and the quality of our rapidly advancing pipeline,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Scorpion. “We are pleased to strengthen the Company's financial position and expand Scorpion’s existing blue-chip investor syndicate with these additional leaders in life sciences who share our commitment to improving outcomes for people living with cancer by broadening the reach and impact of precision medicines.”.

Scorpion首席执行官亚当·弗里德曼（AdamFriedman）医学博士表示：“对此次融资的强劲需求证明了Scorpion持续的临床执行力、我们新兴临床数据的实力以及我们快速发展的渠道的质量。”。“我们很高兴加强公司的财务状况，并扩大Scorpion现有的蓝筹股投资者财团，与这些生命科学领域的其他领导者分享我们的承诺，通过扩大精准药物的覆盖面和影响，改善癌症患者的预后。”。

“At Frazier Life Sciences, our goal is to invest in and develop transformational therapeutics companies. Scorpion continues to display an impressive track record of developing potentially best-in-class and first-in-class selective small molecule compounds for cancer,” said Dr. Albert Cha. “With the combination of Scorpion's clinical progress, advancing pipeline, validating partnerships and veteran leadership team, we believe the Company is well-positioned to rapidly develop therapeutics that will make a meaningful difference in patients’ lives.”.

阿尔伯特·查博士说：“在弗雷泽生命科学公司，我们的目标是投资和发展转型治疗公司。蝎子公司在开发潜在的一流和一流的选择性小分子化合物治疗癌症方面继续保持着令人印象深刻的业绩。”。“结合Scorpion的临床进展、推进渠道、验证合作伙伴关系和经验丰富的领导团队，我们相信该公司能够快速开发治疗方法，从而为患者的生活带来有意义的改变。”。

“Lightspeed is pleased to support Scorpion through this important next phase of growth,” said Dr. Shelley Chu. “The team has made remarkable progress since inception, and we believe Scorpion's targeted approach may be able to overcome the selectivity challenges that plague existing treatment options, ultimately providing better outcomes to patients by offering improvements in both efficacy and safety.

“Lightspeed很高兴支持Scorpion度过下一个重要的成长阶段，”ShelleyChu博士说。“该团队自成立以来取得了显着进展，我们相信Scorpion的有针对性的方法可能能够克服困扰现有治疗方案的选择性挑战，最终通过提高疗效和安全性为患者提供更好的结果。

In particular, Scorpion’s mutant-selective PI3Kα inhibitor, STX-478, has the potential to become a best-in-class treatment for patients with PI3Kα-mutated breast cancer and other solid tumors, and we look forward to partnering with management to further explore STX-478 in mid-stage clinical trials.”.

特别是，蝎子的突变选择性PI3Kα抑制剂STX-478有可能成为PI3Kα突变乳腺癌和其他实体瘤患者的最佳治疗方法，我们期待与管理层合作，在中期临床试验中进一步探索STX-478。”。

Scorpion plans to use the proceeds from this financing to advance its pipeline of differentiated small molecule oncology programs, in particular, to expand clinical development of its allosteric, differentiated, mutant-selective PI3Kα inhibitor, STX-478. Further, the Company will continue to advance its clinical-stage EGFR inhibitor franchise, including STX-721 and STX-241, and its discovery pipeline of next-generation precision oncology therapies..

Scorpion计划利用这笔资金的收益推进其分化小分子肿瘤学项目的管道，特别是扩大其变构，分化，突变选择性PI3Kα抑制剂STX-478的临床开发。此外，该公司将继续推进其临床阶段EGFR抑制剂特许经营权，包括STX-721和STX-241，以及其下一代精准肿瘤疗法的发现渠道。。

About STX-478

关于STX-478

STX-478 was designed to improve outcomes in patients harboring PI3Kα mutations, one of the most prevalent drivers of cancer, occurring in over 166,000 patients per year with breast, gynecological and other solid tumors in the United States alone. In preclinical models, STX-478 demonstrated robust activity across a range of PI3Kα mutations while sparing wild-type PI3Kα inhibition in normal tissues; previous generations of non-selective PI3Kα inhibitors have limited patient benefit due to these on-target toxicities.

STX-478旨在改善PI3Kα突变患者的预后，PI3Kα突变是最常见的癌症驱动因素之一，仅在美国，每年就有超过166000名乳腺癌，妇科和其他实体瘤患者发生。在临床前模型中，STX-478在一系列PI3Kα突变中表现出强大的活性，同时保留了正常组织中野生型PI3Kα的抑制作用；由于这些靶向毒性，前几代非选择性PI3Kα抑制剂对患者的益处有限。

Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by PI3Kα mutations. The program entered the clinic in 2023 and has rapidly advanced, now in multiple expansion cohorts across a range of solid tumors and in breast cancer as monotherapy and in combinations with fulvestrant and CDK4/6 inhibitors.

Scorpion的1/2期临床试验是一项多中心，全球，开放标签研究，旨在评估STX-478在多次递增剂量下对局部晚期或转移性HR+/HER2-乳腺癌和其他实体瘤患者的安全性和耐受性。由PI3Kα突变驱动。该计划于2023年进入诊所，并迅速发展，目前已在一系列实体瘤和乳腺癌的多个扩展队列中作为单一疗法以及与氟维司群和CDK4/6抑制剂联合使用。

The Company remains on-track to disclose initial safety, pharmacokinetic and pharmacodynamic data, and preliminary efficacy data at a future academic conference. To learn more about the first-in-human trial of STX-478, please visit this page..

该公司仍将在未来的学术会议上披露初始安全性，药代动力学和药效学数据以及初步疗效数据。要了解有关STX-478首次人体试验的更多信息，请访问此页面。。

About Scorpion Therapeutics

关于蝎子疗法

Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Scorpion has built a proprietary and fully-integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets.

Scorpion是一家开创性的临床阶段肿瘤公司，它重新定义了精准医学的前沿，为更多的癌症患者提供优化和转化的治疗方法。Scorpion在癌症生物学、药物化学和数据科学领域建立了一个拥有最先进技术的专有和完全集成的平台，目标是始终如一地快速创建针对前所未有的靶标谱的精细选择性小分子化合物。

Scorpion aims to leverage its platform to advance a broad pipeline of wholly-owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets.

Scorpion旨在利用其平台，在三个目标类别中推进广泛的全资优化化合物渠道：针对经过验证的癌基因靶标的同类最佳分子；用于先前不可药用靶标的一流分子；以及用于新型癌症靶标的一流分子。

For more information, visit www.scorpiontx.com..

For more information, visit www.scorpiontx.com..

About Frazier Life Sciences

关于弗雷泽生命科学

Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies and a public fund focused on small and mid-cap public companies.

弗雷泽生命科学公司在全球范围内投资于发现、开发和商业化创新生物制药的私人和上市公司。弗雷泽生命科学管理着超过39亿美元的资本，其中包括专注于公司创建和私人公司的风险基金，以及专注于中小型上市公司的公共基金。

Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London..

自2005年以来，已有60多家弗雷泽生命科学投资组合公司完成了首次公开募股或并购。弗雷泽生命科学团队由40多名具有生物制药专业知识的专业人士组成，主要位于加利福尼亚州帕洛阿尔托（总部）、圣地亚哥、西雅图、波士顿、纽约和伦敦。。

About Lightspeed Venture Partners

关于Lightspeed Venture Partners

Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 500 companies globally including biotechnology companies such as Abata, Ancora, Diagonal, Enlaza, Forty Seven, Personalis, Pheon, Teneobio, Triana, Scorpion, Seismic, Ultima Genomics, Xaira, and more.

Lightspeed Venture Partners是一家多阶段风险投资公司，专注于加速企业、消费者、健康和金融科技领域的颠覆性创新和趋势。在过去的二十年中，光速团队为数百名企业家提供了支持，并在全球范围内帮助建立了500多家公司，包括生物技术公司，如Abata、Ancora、Diagonal、Enlaza、四十七、Personalis、Pheon、Teneobio、Triana、Scorpion、Seismic、Ultima Genomics、Xaira等。

Lightspeed and its global team currently manage $25B in AUM across the Lightspeed platform, with investment professionals and advisors in the U.S., Europe, India, Israel, and Southeast Asia. www.lsvp.com.

Lightspeed及其全球团队目前通过Lightspeed平台管理250亿美元的资产管理规模，在美国、欧洲、印度、以色列和东南亚拥有投资专业人士和顾问。www.lsvp.com。